Keep an eye on Cybin (SYM: CYBN).
After bottoming out at around $6.50, the stock is now up to $12.57 and could race even higher.
For one, Donald Trump wants Robert Kennedy to be a part of his health care team. Reportedly, psychedelic treatments for mental health issues are at the top of Kennedy’s list. In fact, as he wrote on X just last month, the “FDA’s war on public health is about to end,” noting that he wants to reverse the “aggressive suppression of psychedelics.”
Two, Cybin just “announced the initiation of PARADIGM, its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder. The program name, PARADIGM, represents the Company’s belief that CYB003 could have the potential for a paradigm shift in the treatment of depression,” as noted in the company’s most recent press release.
Even better, the company will hold a conference call on Monday, November 18 before market open. “The event will be hosted by Cybin’s Chief Executive Officer, Doug Drysdale, and Cybin’s Chief Medical Officer, Amir Inamdar, and will include presentation of 12-month efficacy and safety data from the Company’s Phase 2 study of CYB003 in Major Depressive Disorder and an overview of the design of its recently initiated Phase 3 PARADIGM™ program in CYB003,” according to a press release.
